Esomeprazole + Lansoprazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Erosive Esophagitis
Conditions
Erosive Esophagitis
Trial Timeline
Dec 1, 2002 → Aug 1, 2003
NCT ID
NCT00641602About Esomeprazole + Lansoprazole
Esomeprazole + Lansoprazole is a approved stage product being developed by AstraZeneca for Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00641602. Target conditions include Erosive Esophagitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00352261 | Approved | Completed |
| NCT00644735 | Approved | Completed |
| NCT00641602 | Approved | Completed |
Competing Products
20 competing products in Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 85 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Nexium 20mg + Nexium 10mg | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 85 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| esomeprazole magnesium (oral medication) | AstraZeneca | Approved | 85 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 51 |
| Omeprazole/sodium bicarbonate | Bausch Health | Approved | 80 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 1 | 28 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan | Phathom Pharmaceuticals | Pre-clinical | 18 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |